Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Phase I and Phase II clinical trials of androst-5-ene-3β,7β,17β-triol.

Stickney DR, Ahlem CN, Morgan E, Reading CL, Onizuka N, Frincke JM.

Am J Transl Res. 2011 May 15;3(3):275-83. Epub 2011 Apr 12.

2.

Pharmacology and immune modulating properties of 5-androstene-3β,7β,17β-triol, a DHEA metabolite in the human metabolome.

Ahlem CN, Auci DL, Nicoletti F, Pieters R, Kennedy MR, Page TM, Reading CL, Enioutina EY, Frincke JM.

J Steroid Biochem Mol Biol. 2011 Sep;126(3-5):87-94. doi: 10.1016/j.jsbmb.2011.04.010. Epub 2011 May 5.

PMID:
21570467
3.

Androst-5-ene-3β,7α/β,17β-triols, their plasma levels and dependence on the hypothalamic-pituitary-adrenal axis.

Stárka L, Hill M, Kolatorova L, Dušková M.

Steroids. 2018 Jun;134:88-95. doi: 10.1016/j.steroids.2018.02.005. Epub 2018 Feb 23.

PMID:
29477344
4.

Studies of the pharmacology of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol, a synthetic anti-inflammatory androstene.

Ahlem CN, Kennedy MR, Page TM, Reading CL, White SK, McKenzie JJ, Cole PI, Stickney DR, Frincke JM.

Int J Clin Exp Med. 2011;4(2):119-35. Epub 2011 Apr 23.

5.

17α-Ethynyl-androst-5-ene-3β,7β,17β-triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson's Disease.

Nicoletti F, Philippens I, Fagone P, Ahlem CN, Reading CL, Frincke JM, Auci DL.

Parkinsons Dis. 2012;2012:969418. doi: 10.1155/2012/969418. Epub 2012 Sep 26.

6.

Biotransformation of dehydroepiandrosterone with Macrophomina phaseolina and β-glucuronidase inhibitory activity of transformed products.

Choudhary MI, Zafar S, Khan NT, Ahmad S, Noreen S, Marasini BP, Al-Khedhairy AA, Atta-Ur-Rahman.

J Enzyme Inhib Med Chem. 2012 Jun;27(3):348-55. doi: 10.3109/14756366.2011.590804. Epub 2011 Jul 21.

PMID:
21774747
7.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
8.

Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.

Hübner R, Högemann AM, Sunzel M, Riddell JG.

J Hum Hypertens. 1997 Sep;11 Suppl 2:S19-25.

PMID:
9331000
10.
11.

Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.

Raccah D, Miossec P, Esposito V, Niemoeller E, Cho M, Gerich J.

Diabetes Metab Res Rev. 2015 Feb;31(2):204-11. doi: 10.1002/dmrr.2588. Epub 2014 Sep 16.

PMID:
25115916
12.
13.

Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.

Rohatagi S, Gillen M, Aubeneau M, Jan C, Pandit B, Jensen BK, Rhodes G.

Int J Clin Pharmacol Ther. 2001 Mar;39(3):126-34.

PMID:
11396753
14.

Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.

Rosenberg G, Angel I, Kozak A.

Br J Clin Pharmacol. 2005 Jul;60(1):7-16.

15.

Analytical strategies for the detection of non-labelled anabolic androgenic steroids in nutritional supplements.

Parr MK, Geyer H, Reinhart U, Schänzer W.

Food Addit Contam. 2004 Jul;21(7):632-40.

PMID:
15370836
16.

Clevidipine: a review of its use in the management of acute hypertension.

Deeks ED, Keating GM, Keam SJ.

Am J Cardiovasc Drugs. 2009;9(2):117-34. doi: 10.2165/00129784-200909020-00006. Review.

PMID:
19331440
17.

Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.

Namour F, Vanhoutte FP, Beetens J, Blockhuys S, De Weer M, Wigerinck P.

Drugs R D. 2012 Sep 1;12(3):141-63. doi: 10.2165/11633120-000000000-00000.

18.

Seized designer supplement named "1-Androsterone": identification as 3β-hydroxy-5α-androst-1-en-17-one and its urinary elimination.

Parr MK, Opfermann G, Geyer H, Westphal F, Sönnichsen FD, Zapp J, Kwiatkowska D, Schänzer W.

Steroids. 2011 May;76(6):540-7. doi: 10.1016/j.steroids.2011.02.001. Epub 2011 Feb 16.

PMID:
21310167
19.
20.

Redox reactions of dehydroepiandrosterone and its metabolites in differentiating 3T3-L1 adipocytes: A liquid chromatographic-mass spectrometric study.

Marwah A, Gomez FE, Marwah P, Ntambi JM, Fox BG, Lardy H.

Arch Biochem Biophys. 2006 Dec 1;456(1):1-7. Epub 2006 Oct 10. Erratum in: Arch Biochem Biophys. 2007 Sep 1;465(1):302.

PMID:
17078923

Supplemental Content

Support Center